Amber Therapeutics
Jacob Kerr is an engineer at Amber Therapeutics since January 2023, following a role as a data scientist at Charco from August to December 2022. Previous experience includes a research internship at the University of Oxford's Department of Engineering Science in June 2020, where Jacob modified a MATLAB program for quantitative analysis of microvessel networks. Jacob gained valuable work experience through internships at Rolls-Royce, Airbus, and Rutherford Appleton Laboratory, each lasting one week in 2017. Jacob holds a Master of Engineering in Biotechnology from the University of Oxford, completed in 2022, and attended Hampton School from 2011 to 2018.
This person is not in any teams
Amber Therapeutics
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a multidisciplinary team of clinicians, translational neuroengineers, medtech industry professionals and experienced entrepreneurs focused on developing transformational therapy innovation for major unmet medical conditions. The Company is backed by Oxford Science Enterprises and 8VC.